Tom Hogan

Prince Fielder That guy rocked.

In other words, the Local/Cloud agent crossover-era has not only begun, but it's being accepted and encouraged by Investors and users alike. If my original theory holds as it relates to $META, Zuck's next move will be shipping a multi-agent local/cloud stack with shared context and memory windows. This would naturally lead to the creation of the new industry for him to dominate: digital ads in the agentic ecosystem. If I had to guess, the targeted sub-domain will align more with the Paperclip AI-model rather than OpenClaw, but it doesn't matter either way. What matters is META is already there and we're watching frontiers follow Manus, not the other way around. Zuck was roasted for Manus and Moltbook given the lack of short-term ROI, but he's following his standard playbook: See Instagram and WhatsApp acquisitions. x.com/ManusAI/status…

Late to putting my thoughts out on this, but a 6-month old has an incredible ability to delay life, but I digress. Some thoughts here. This follow-up announcement 13-days later from Manus is interesting for a few reasons, and I think it matters more than I originally thought. I'll dive into that shortly, but staying focused on $META /Manus first, quick recap: I) March 16th - Manus ships CLI on local machines, which was the first "blurred" lines moment as mentioned in the thread above^ II) March 16th - $GOOGL announces that GWS will be available via Manus only a few hours later III) March 17th - $NVDA ships NemoClaw at GTC -> which follows OpenClaw's open-source model, as Jensen said IV) March 19th - OpenAI announces superapp -> following Anthropic's unified Claude/Agent model + Manus desktop V) March 23rd - Anthropic ships Computer Use + Dispatch -> following Manus's desktop-to-phone pattern via the CLI blurred lines theme.

"Today, we're taking Manus out of the cloud and putting it on your desktop" If you want to know why $META bought Moltbook, or if you laughed at or were confused by it, the answer's right here. I am still confused how/why this hasn't blown up, maybe $NVDA and OpenClaw/Paperclip news? Regardless, this is wild. In the last ~48 hours: I) Moltbook's co-founders started at Meta Superintelligence Labs II) $NBIS deal announced — $27B over 5 years for dedicated AI compute III) Quietly rolled out Instagram, Insta Creator Marketplace + Meta Ads Manager as native Manus connectors IV) My Computer launch giving Manus/$META access to CLI on local machines... with access to files, apps, terminal, and browser Zuck already owns the social media data space and the ads layer, which was facilitated by the Instagram acquisition. Instagram took Meta from the internet to peoples' phones/pockets and now he's doubling back, moving into a layer of access that no other company has ($GOOGL) or wants ($AAPL). All of that^ doesn't even touch on the fact that they can now play gatekeeper in a completely new industry that they create: selling ads digitally in the agent-to-agent (A2A) layer. The $NBIS deal locks up the compute to play gatekeeper, at least for a little while. Meta went from owning social data and the ads layer alongside the likes of the other big players, but now he has what they don't: local access with no remaining boundaries to persistent data capture of our lives, both on and offline. Manus gave them the ticket to play - just like Insta. Last thought: I think the hardest aspect grasp is that the negative space between nodes - humans, agents, and digital economies - feels like it's now smaller than the mapped space. Curious to see who goes next, but I assume it will be sooner than later.

The long wait is over: Andrew Painter’s debut 👀

That was awesome. 🇺🇸

WHAT A TILT IN PHILLY Old school.

🦅😤

On the first play of the game, on the night they were honoring Allen Iverson and the 2001 Sixers, Nick Nurse dialed up an Iverson Cut to get Tyrese Maxey a layup. I leaned over to @KyleNeubeck and said that had to be intentional. Kyle tracked Nurse down and verified that it was.

Full intros as the Sixers honor the 2001 Eastern Conference champs

Mike Posner sang a “healed” version of his hit song “I Took A Pill In Ibiza”

Ryan Howard chases after the umpire who ejected him in the 14th inning, a breakdown

Not really sure why everyone’s upset about the Phillies… Crawford is coming up, Adolis gives you righty power and a dynamic we haven’t had, Edmundo will continue playing more and you’ve got promising MiLB swing players. Just relax #RingTheBell

Can you read 900 words per minute? Try it.

Someone want to explain why the Eagles decide to turn the offense on for one drive a game

Omg Mahomes

Concrete and impressive 2026 and midterm guidance given by $SRTA at the Investor Conference. Looking forward to the market recognizing Strata’s growth potential in this recession-proof part of the medical services industry.

Impressive Investor Day today from Strata Critical Medical - $SRTA. I expect to go into more detail later this week with a research piece, but some highlights listed below for those looking for LT names in the SMID space: 1) Executive Transition was seamless post-Blade divestiture to $JOBY. Will Heyburn and Melissa Tomkiel bring an interesting dynamic to the space as Co-CEOs. Both understand the company’s opportunity set and how to effectively consolidate a fragmented industry. 2) The acquisition of Keystone seems to be a homerun. Keystone’s leadership team and domain expertise is truly impressive. I’m not a HC guy, yet they were able to convey how they were successful before, where they can add dynamic growth, organically or via M&A, and their framework for effective uses of capital pairs nicely with Strata’s approach. 3) The industry is far more fragmented than almost any other industry I’ve encountered. -Industry Rules & Regulations seem to be playing catchup given all the changes. With industry standards still in flux, companies like Strata will set the standard, making it nearly impossible for small players to take market share. -Small players are ripe to be taken out at low multiples given how hard it is to scale and lack of infrastructure to expand horizontally or vertically without serious execution risk. This doesn’t account for the aforementioned high-bar standards being set as we speak. 4) Organ procurement, transportation (Air/Ground), and related procedures are not for the faint of heart, nor “exciting” given the complexities, but it’s a damn good business if executed properly. Market multiples will remain compressed until consolidation occurs, but hard to see multiples remaining compressed much longer. 5) Scalability is hard for large players too, but once the gap is bridged, like in the case of Strata and Keystone, economies of scale create wide competitive moats and gives Strata significant leverage in future M&A. 6) Organic growth continues to move along in mid-teens, but acquisitions speed up customer acquisition timelines significantly. Once converted, new customers also provide incremental revs across business segments, like clinical services, further improving margins and long-term growth. 7) Advancements (2018 onwards) in MedTech and improved procedures have expanded TAM due to longer viability of organs for transplants. Longer viability = more serviceable contracts = further entrenchment as the leader in the space. TAM remains relatively small, but RoC has picked up with recent advancements. Important to note that the market is insulated from the economy, making it attractive from a defensive perspective as well. All-in-all, we remain impressed and look forward to watching the $SRTA team execute for shareholders. Disclosure: Alpha Loop Capital is long $SRTA

👇👇👇